Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × Valacyclovir × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Leukemia 2 Waldenstrom Macroglobulinemia 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Stomatitis 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Epstein-Barr Virus Infections 1 Cytomegalovirus Infections 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1 Adenocarcinoma 1

Interventions

Temozolomide 56 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 15 Specimen Handling 9 Carmustine 9 Carboplatin 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Nivolumab 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3 dabrafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00589875 2024-04-03

BrTK02

Candel Therapeutics, Inc.

Phase 2 Completed

52 enrolled 10 charts

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡